Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia
复制标题
DOI：
10.1111/j.1365-2141.2010.08387.x
复制
发表时间：
2010-12-01
影响因子：
6.5
通讯作者：
Appelbaum, Frederick R.
中科院分区：
文献类型：
--
作者：
Advani, Anjali S.;Gundacker, Holly M.;Appelbaum, Frederick R.
氯法拉滨和阿糖胞苷靶向DNA合成和复制的不同步骤，在体内具有协同作用，并且具有不重叠的毒性，使这种组合成为治疗急性淋巴细胞白血病的潜在希望。37例患者接受了治疗。中位年龄为41岁，44%的患者为>=第二次复发或难治性疾病，59%的患者细胞遗传学风险较低。36例患者中有6例（17%）在计数完全恢复或未完全恢复的情况下实现了完全缓解；中位总生存期为3个月。核苷转运蛋白表达不能预测预后。该方案缺乏足够的活性，不值得进一步试验。
P>Clofarabine and cytarabine target different steps in DNA synthesis and replication, are synergistic in vivo, and have non-overlapping toxicities, making this combination a potentially promising treatment for acute lymphocytic leukaemia. Thirty-seven patients were treated. The median age was 41 years, 44% of patients were either in >= 2nd relapse or had refractory disease and 59% of patients had poor risk cytogenetics. Six out of 36 patients (17%) achieved a complete remission with or without complete count recovery; median overall survival was 3 months. Nucleoside transporter expression did not predict outcome. This regimen lacked sufficient activity to warrant further testing.